Oncology Research and Treatment
Original Article · Originalarbeit
Age at Onset of Bilateral Breast Cancer, the Presence of Hereditary BRCA1, BRCA2, CHEK2 Gene Mutations and Positive Family History of CancerSkasko E.a · Kluska A.a · Niwińska A.b · Kwiatkowska E.a · Bałabas A.a · Piątkowska M.a · Dąbrowska M.a · Nowakowska D.c · Pieńkowski T.ba Department of Endocrinology, b Department of Breast Cancer and Reconstructive Surgery, c Outpatient Chemotherapy Unit, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: March 13, 2009
Issue release date: April 2009
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)
For additional information: https://www.karger.com/ORT
Abstract
Background: Our research focused on the relations between the age at onset of bilateral breast cancer and the prevalence of selected hereditary BRCA1, BRCA2 and CHEK2 gene mutations with reference to their positive family history of cancer. Methods: The DNA of peripheral blood lymphocytes of patients was examined for the presence of selected hereditary mutations in the BRCA1, BRCA2 and CHEK2 genes, using molecular biology techniques. The family history of neoplasms was also analyzed. Results: The following mutations in the BRCA1 gene were identified: 185delAG, C61G, 5382insC, 3875 del11ins7, and R1751X. In the BRCA2 gene, the 9631delC and A9599T mutations were found. In the CHEK2 gene, the 1100delC and I157T mutations were identified. BRCA1/2 gene mutations were identified in 19.4% of patients and CHEK2 gene mutations in 7%. Conclusions: It was shown that the presence of the mutations in the BRCA1/2 genes among patients with bilateral breast cancer is associated with an earlier occurrence of the first and the second breast cancer than in patients without hereditary mutations in these genes (a difference of 7.2–8.4 years). In patients with CHEK2 gene mutations, breast cancer occurred 2.1–3.8 years earlier than in patients without mutations in the CHEK2 gene.
© 2009 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Published online: March 13, 2009
Issue release date: April 2009
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)
For additional information: https://www.karger.com/ORT
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission